Michael J. Pellini - 04 Mar 2025 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Reporting relationship: Director
Issuer ticker: ADPT
Reported as of: 04 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Mar 2025, 19:17:15 UTC
Prior SEC filing: 25 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Michael J Pellini by Kyle Piskel, Attorney-in-Fact

Key filing fact

Michael J. Pellini filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 06 Mar 2025.

Key facts

This page summarizes Michael J. Pellini's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Mar 2025, 19:17.

Change

Previous filing in this sequence was filed on 25 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADPT transaction

Common Stock

Award

Transaction value: $0
Shares: +15,394
Change %: +28%
Price: $0.000000
Shares after: 69,690
Date: 04 Mar 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADPT transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +23,726
Change %
Price: $0.000000
Shares after: 23,726
Date: 04 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,726
Exercise price: $8.12
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.